GeneDx Holdings Corp. (NASDAQ:WGS) Receives $112.80 Average Target Price from Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $124.2222.

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, October 8th. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. BTIG Research raised their price objective on shares of GeneDx from $140.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company lifted their target price on shares of GeneDx from $78.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 30th. Finally, Piper Sandler increased their price target on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $136.91 on Friday. The company has a 50 day simple moving average of $124.27 and a two-hundred day simple moving average of $98.98. GeneDx has a fifty-two week low of $55.17 and a fifty-two week high of $146.00. The company has a market capitalization of $3.93 billion, a price-to-earnings ratio of 1,521.22 and a beta of 1.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.70 and a current ratio of 2.71.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The firm had revenue of $116.74 million for the quarter, compared to analysts’ expectations of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. Analysts expect that GeneDx will post 0.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other GeneDx news, Director Casdin Capital, Llc sold 500,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the sale, the director directly owned 3,007,164 shares in the company, valued at approximately $363,566,127.60. This trade represents a 14.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jason Ryan sold 38,072 shares of the business’s stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total value of $4,846,565.60. Following the completion of the transaction, the director owned 103,284 shares of the company’s stock, valued at $13,148,053.20. This represents a 26.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 556,375 shares of company stock valued at $67,569,247. Insiders own 29.60% of the company’s stock.

Hedge Funds Weigh In On GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in shares of GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock worth $39,000 after acquiring an additional 264 shares during the period. US Bancorp DE boosted its holdings in GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after purchasing an additional 548 shares during the last quarter. AlphaQuest LLC boosted its holdings in GeneDx by 351.5% in the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares during the last quarter. KBC Group NV bought a new stake in GeneDx in the 1st quarter worth approximately $81,000. Finally, PNC Financial Services Group Inc. purchased a new stake in GeneDx during the 1st quarter valued at $132,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.